New Canadian Insights on Switching to Longer-Acting Therapy for Hemophilia A – WFH
World Federation of hemphilia (WFH) shared on X about a recent article by Davide Matino et al, published in Haemophilia Journal:
”A new Canadian study explores outcomes for people with hemophilia A (12+) who switched to a longer-acting treatment, looking at bleeding, quality of life, infusion frequency, and treatment satisfaction.”
Title: Canadian Clinical Experience on Switching From Standard Half-life Recombinant Factor VIII (rFVIII), Octocog Alfa, to Extended Half-life rFVIII, Damoctocog Alfa Pegol, in Persons With Haemophilia A ≥ 12 Years Followed in a Comprehensive Haemophilia Care Program in Canada
Authors: Davide Matino, Anthony K. C. Chan, Kay Decker, Emma Iserman, Andrea N. Edginton, Olayide Oladoyinbo, Elisabetta Trinari, Arun Keepanasseril, Alfonso Iorio
Read the Full Article on Haemophilia Journal
Stay updated on all scientific advances with Hemostasis Today.
-
Sep 22, 2026, 16:45Claudiu Stoicescu: Are We Starting Cardiovascular Risk Assessment Too Late?
-
Sep 22, 2026, 16:20Ila Bappa Ibrahim: Bringing Sickle Cell Innovation Closer to Communities
-
Sep 22, 2026, 16:02Ana Pedrero Gil: Peri-operative Management of Patients Undergoing Day Surgery
-
Sep 22, 2026, 15:27Zia Ullah: RBC-Derived Extracellular Vesicles as Potential Biomarkers of Thrombotic Risk in Dengue
-
Sep 22, 2026, 15:01Lesley Van Wyk: What Each Iron Markers Actually Mean
-
Sep 22, 2026, 14:37Chokri Ben Lamine։ Saudi Arabia Leads A New Milestone In Hemophilia A Care
-
Sep 22, 2026, 13:58Giulia Passaniti: Dual Inferior Vena Cava Anatomy in Tetralogy of Fallot
-
Sep 22, 2026, 13:35Michael Miyamoto: Scaling Guideline Based Lipid Management in Community Practice
-
Sep 22, 2026, 13:15Suvro Sankha Datta: Developing Blood Group Genotyping Platform Using a Gold-Oligo